PURPOSE: Preconception radiation and chemotherapy have the potential to produce germ cell mutations leading to genetic disease in the next generation. Dose-response relationships were evaluated between cancer treatments and untoward pregnancy outcomes. PATIENTS AND METHODS: A case-cohort study was conducted involving 472 Danish survivors of childhood and adolescent cancer and their 1,037 pregnancies. Adverse outcomes included 159 congenital malformations, six chromosomal abnormalities, seven stillbirths, and nine neonatal deaths. Preconception radiation doses to the gonads, uterus, and pituitary gland and administered chemotherapy were quantified based on medical records and related to adverse outcomes using a generalized estimating equation model. RESULTS: No statistically significant associations were found between genetic disease in children and parental treatment with alkylating drugs or preconception radiation doses to the testes in male and ovaries in female cancer survivors. Specifically, the risk of genetic disease was similar among the children of irradiated survivors when compared with nonirradiated survivors (relative risk [RR], 1.02; 95% CI, 0.59 to 1.44; P = .94). A statistically significant association between abdomino-pelvic irradiation and malformations, stillbirths, and neonatal deaths was not seen in the children of female survivors overall (P = .07) or in the children of mothers receiving high uterine doses (mean, 13.5 Gy; max, 100 Gy; RR, 2.3; 95% CI, 0.95 to 5.56). CONCLUSION: Mutagenic chemotherapy and radiotherapy doses to the gonads were not associated with genetic defects in children of cancer survivors. However, larger studies need to be conducted to further explore potential associations between high-dose pelvic irradiation and specific adverse pregnancy outcomes.
PURPOSE: Preconception radiation and chemotherapy have the potential to produce germ cell mutations leading to genetic disease in the next generation. Dose-response relationships were evaluated between cancer treatments and untoward pregnancy outcomes. PATIENTS AND METHODS: A case-cohort study was conducted involving 472 Danish survivors of childhood and adolescent cancer and their 1,037 pregnancies. Adverse outcomes included 159 congenital malformations, six chromosomal abnormalities, seven stillbirths, and nine neonatal deaths. Preconception radiation doses to the gonads, uterus, and pituitary gland and administered chemotherapy were quantified based on medical records and related to adverse outcomes using a generalized estimating equation model. RESULTS: No statistically significant associations were found between genetic disease in children and parental treatment with alkylating drugs or preconception radiation doses to the testes in male and ovaries in female cancer survivors. Specifically, the risk of genetic disease was similar among the children of irradiated survivors when compared with nonirradiated survivors (relative risk [RR], 1.02; 95% CI, 0.59 to 1.44; P = .94). A statistically significant association between abdomino-pelvic irradiation and malformations, stillbirths, and neonatal deaths was not seen in the children of female survivors overall (P = .07) or in the children of mothers receiving high uterine doses (mean, 13.5 Gy; max, 100 Gy; RR, 2.3; 95% CI, 0.95 to 5.56). CONCLUSION: Mutagenic chemotherapy and radiotherapy doses to the gonads were not associated with genetic defects in children of cancer survivors. However, larger studies need to be conducted to further explore potential associations between high-dose pelvic irradiation and specific adverse pregnancy outcomes.
Authors: J F Winther; R Sankila; J D Boice; H Tulinius; A Bautz; L Barlow; E Glattre; F Langmark; T R Möller; J J Mulvihill; G H Olafsdottir; A Ritvanen; J H Olsen Journal: Lancet Date: 2001-09-01 Impact factor: 79.321
Authors: Daniel M Green; Eve M Peabody; Bin Nan; Susan Peterson; John A Kalapurakal; Norman E Breslow Journal: J Clin Oncol Date: 2002-05-15 Impact factor: 44.544
Authors: Daniel M Green; John A Whitton; Marilyn Stovall; Ann C Mertens; Sarah S Donaldson; Frederick B Ruymann; Thomas W Pendergrass; Leslie L Robison Journal: Am J Obstet Gynecol Date: 2002-10 Impact factor: 10.693
Authors: Monika L Metzger; Lillian R Meacham; Briana Patterson; Jacqueline S Casillas; Louis S Constine; Nobuko Hijiya; Lisa B Kenney; Marcia Leonard; Barbara A Lockart; Wendy Likes; Daniel M Green Journal: J Clin Oncol Date: 2013-02-04 Impact factor: 44.544
Authors: Gregory V Kryukov; Craig M Bielski; Kaitlin Samocha; Menachem Fromer; Sara Seepo; Carleen Gentry; Benjamin Neale; Levi A Garraway; Christopher J Sweeney; Mary-Ellen Taplin; Eliezer M Van Allen Journal: Clin Cancer Res Date: 2015-12-02 Impact factor: 12.531
Authors: Wendy van Dorp; Riccardo Haupt; Richard A Anderson; Renee L Mulder; Marry M van den Heuvel-Eibrink; Eline van Dulmen-den Broeder; H Irene Su; Jeanette Falck Winther; Melissa M Hudson; Jennifer M Levine; W Hamish Wallace Journal: J Clin Oncol Date: 2018-06-06 Impact factor: 44.544
Authors: Laura-Maria Madanat-Harjuoja; Päivi M Lähteenmäki; Tadeusz Dyba; Mika Gissler; John D Boice; Nea Malila Journal: Acta Oncol Date: 2013-01-17 Impact factor: 4.089